Extasy Grinn, LCSW, CAP ICADC | |
2030 Chilhowee Medical Park, Maryville, TN 37804-5285 | |
(865) 982-3400 | |
(865) 238-2034 |
Full Name | Extasy Grinn |
---|---|
Gender | Female |
Speciality | Social Worker |
Location | 2030 Chilhowee Medical Park, Maryville, Tennessee |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124534912 | NPI | - | NPPES |
Entity Name | Athena Consulting And Psychological Services, Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1336292465 PECOS PAC ID: 5294719795 Enrollment ID: O20040614001008 |
News Archive
Physicians have a new fast-acting option for controlling the potentially crippling effects of acute agitation in patients suffering with schizophrenia and bipolar mania. The U.S. Food and Drug Administration (FDA) has approved Zyprexa® IntraMuscular (olanzapine for injection), an injectable form of Lilly's top-selling medication.
The 90-year-old woman in the San Diego-area nursing home was quite clear, said Dr. Karl Steinberg. She didn't want aggressive measures to prolong her life. If her heart stopped, she didn't want CPR.
Patients with neck injuries incur increased health and social costs-which also affect their spouses and may begin years before the initial injury, reports a study in the March 1 issue of Spine.
In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.
› Verified 8 days ago
Entity Name | Savida Health, Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1861118846 PECOS PAC ID: 4082809967 Enrollment ID: O20221228001386 |
News Archive
Physicians have a new fast-acting option for controlling the potentially crippling effects of acute agitation in patients suffering with schizophrenia and bipolar mania. The U.S. Food and Drug Administration (FDA) has approved Zyprexa® IntraMuscular (olanzapine for injection), an injectable form of Lilly's top-selling medication.
The 90-year-old woman in the San Diego-area nursing home was quite clear, said Dr. Karl Steinberg. She didn't want aggressive measures to prolong her life. If her heart stopped, she didn't want CPR.
Patients with neck injuries incur increased health and social costs-which also affect their spouses and may begin years before the initial injury, reports a study in the March 1 issue of Spine.
In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Extasy Grinn, LCSW, CAP ICADC 4799 Palmbrooke Cir, West Palm Beach, FL 33417-7534 Ph: (561) 876-8751 | Extasy Grinn, LCSW, CAP ICADC 2030 Chilhowee Medical Park, Maryville, TN 37804-5285 Ph: (865) 982-3400 |
News Archive
Physicians have a new fast-acting option for controlling the potentially crippling effects of acute agitation in patients suffering with schizophrenia and bipolar mania. The U.S. Food and Drug Administration (FDA) has approved Zyprexa® IntraMuscular (olanzapine for injection), an injectable form of Lilly's top-selling medication.
The 90-year-old woman in the San Diego-area nursing home was quite clear, said Dr. Karl Steinberg. She didn't want aggressive measures to prolong her life. If her heart stopped, she didn't want CPR.
Patients with neck injuries incur increased health and social costs-which also affect their spouses and may begin years before the initial injury, reports a study in the March 1 issue of Spine.
In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.
› Verified 8 days ago